Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy

Autoimmune blistering diseases of the skin have all been reported in patients with psoriasis, bullous pemphigoid (BP) being the most frequently observed. The pathophysiologic triggers for BP in psoriatic patients are unclear. Recent observational studies have suggested that chronic psoriatic inflammation may cause pathological changes to the basement membrane zone, thus inducing autoimmunity against BP antigens through cross reactivity and “epitope spreading.” The coexistence of BP and psoriasis poses challenging therapeutic dilemmas related to the incompatibility of their standard treatments. Considering the probable common immunologic mechanisms in the pathogenesis of these inflammatory skin disorders, a suitable treatment regimen should be applied for their parallel control. We report three patients, who developed BP in the course of preceding long-lasting psoriasis. Secukinumab was administered as first-line treatment with promising therapeutic effect for both skin disorders and long-term disease control in two of the cases. In the third case, parallel disease control was initially achieved with methotrexate. A few years later, secukinumab was used for the treatment of a relapse of both dermatoses but worsening of BP was observed and methotrexate was reintroduced. Our experience on the therapeutic potential of secukinumab in BP is supported by the data in the literature. Recently, it was demonstrated that the proinflammatory cytokine IL17A has a functional role in the process of skin inflammation in BP, similarly to psoriasis. IL17A inhibition has emerged as a promising therapeutic strategy in patients with extensive or refractory BP but paradoxical development of BP after secukinumab treatment for psoriasis has also been described. This controversy emphasizes the need for further investigation into the development of optimal treatment strategies and recommendations.

[1]  C. Foti,et al.  The Intriguing Links between Psoriasis and Bullous Pemphigoid , 2022, Journal of clinical medicine.

[2]  A. Offidani,et al.  Bullous Pemphygoid and Novel Therapeutic Approaches , 2022, Biomedicines.

[3]  W. Li,et al.  Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid , 2022, The Journal of dermatology.

[4]  T. Tsai,et al.  Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review , 2022, American Journal of Clinical Dermatology.

[5]  R. Bergman,et al.  Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV) , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  K. Schäkel,et al.  Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO) , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  Ying Xie,et al.  Coexistence of Anti-p200 Pemphigoid and Psoriasis: A Systematic Review , 2022, Frontiers in Immunology.

[8]  C. McCormack,et al.  Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report , 2022, The Australasian journal of dermatology.

[9]  M. Alaibac,et al.  Bullous pemphigoid: An immune disorder related to aging (Review). , 2021, Experimental and therapeutic medicine.

[10]  Lingyi Lu,et al.  Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis , 2021, The Journal of dermatology.

[11]  J. Sinagra,et al.  Bullous Pemphigoid: Trigger and Predisposing Factors , 2020, Biomolecules.

[12]  D. Zillikens,et al.  Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[13]  K. Kridin,et al.  The Bidirectional Association Between Bullous Pemphigoid and Psoriasis: A Population-Based Cohort Study , 2020, Frontiers in Medicine.

[14]  K. Kridin,et al.  Increased Risk of Pemphigus among Patients with Psoriasis: A Large-scale Cohort Study , 2020, Acta dermato-venereologica.

[15]  G. Ogg,et al.  Role of regulatory T cells in psoriasis pathogenesis and treatment , 2020, The British journal of dermatology.

[16]  M. Amagai,et al.  Autoimmune bullous skin diseases, pemphigus and pemphigoid. , 2020, The Journal of allergy and clinical immunology.

[17]  O. Abbas,et al.  Update on the use of dapsone in dermatology , 2020, International journal of dermatology.

[18]  Y. Tada,et al.  Secukinumab decreased circulating anti‐BP180‐NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid , 2019, The Journal of dermatology.

[19]  H. Busch,et al.  IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. , 2019, Journal of autoimmunity.

[20]  J. Krueger,et al.  Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis , 2018, The Journal of Immunology.

[21]  K. Phan,et al.  Association between bullous pemphigoid and psoriasis: Systematic review and meta‐analysis of case‐control studies , 2018, The Australasian journal of dermatology.

[22]  T. Dainichi,et al.  Interaction of Psoriasis and Bullous Diseases , 2018, Front. Med..

[23]  W. Boehncke,et al.  The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond , 2018, Front. Immunol..

[24]  M. Schön,et al.  The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis , 2018, Front. Immunol..

[25]  L. Bonifaz,et al.  SEB Stimulation Induces Functional Pathogenic Features in Th17 Cells from Psoriasis Patients. , 2018, The Journal of investigative dermatology.

[26]  M. Furue,et al.  Autoimmunity and autoimmune co‐morbidities in psoriasis , 2018, Immunology.

[27]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[28]  T. Tsai,et al.  Development of bullous pemphigoid during secukinumab treatment for psoriasis , 2017, The Journal of dermatology.

[29]  F. Antonicelli,et al.  A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  S. Langan,et al.  Psoriasis and comorbid diseases: Epidemiology. , 2017, Journal of the American Academy of Dermatology.

[31]  F. Antonicelli,et al.  Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome , 2015, Scientific Reports.

[32]  H. Koga,et al.  Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases. , 2015, Journal of the American Academy of Dermatology.

[33]  H. Koenen,et al.  Cellular sources of IL‐17 in psoriasis: a paradigm shift? , 2014, Experimental dermatology.

[34]  J. Blalock,et al.  Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid , 2014, The Journal of investigative dermatology.

[35]  O. FitzGerald,et al.  Th17 and Th22 cells in psoriatic arthritis and psoriasis , 2013, Arthritis Research & Therapy.

[36]  U. Mrowietz,et al.  Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[37]  O. Stasikowska-Kanicka,et al.  IL-17 Expression in Dermatitis Herpetiformis and Bullous Pemphigoid , 2013, Mediators of inflammation.

[38]  R. Schwartz,et al.  Cardiovascular aspects of psoriasis: an updated review , 2013, International journal of dermatology.

[39]  D. Tokunaga,et al.  Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept , 2013, The Journal of dermatology.

[40]  L. Herrinton,et al.  The association of psoriasis with autoimmune diseases. , 2012, Journal of the American Academy of Dermatology.

[41]  P. Mortensen EPIDEMIOLOGY , 2012, Schizophrenia Research.

[42]  T. Dainichi,et al.  Lesional Th17 cells and regulatory T cells in bullous pemphigoid , 2011, Experimental dermatology.

[43]  R. Rashmi,et al.  The role of drugs in the induction and/or exacerbation of psoriasis , 2010, International journal of dermatology.

[44]  J. Bystryn,et al.  Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid. , 2010, Medical hypotheses.

[45]  S. Vassileva Drug-induced pemphigoid: bullous and cicatricial. , 1998, Clinics in dermatology.

[46]  T. Hashimoto,et al.  Psoriasis vulgaris coexistent with epidermolysis bullosa acquisita , 1997, The British journal of dermatology.

[47]  H. Shimizu,et al.  Coexistence of psoriasis and an unusual IgG‐mediated subepidermal bullous dermatosis: identification of a novel 200‐kDa lower lamina lucida target antigen , 1996, The British journal of dermatology.

[48]  N. Tsankov,et al.  Burn-induced bullous pemphigoid. , 1994, Journal of the American Academy of Dermatology.

[49]  B. Stephens The Beat Goes On , 1991, Science.

[50]  A. Menter,et al.  Erythrodermic psoriasis: Precipitating factors, course, and prognosis in 50 patients , 1989 .

[51]  P. Aronson,et al.  Bullous pemphigoid in psoriatic lesions. , 1989, Journal of the American Academy of Dermatology.

[52]  N. Tsankov,et al.  Psoriasis and drugs: influence of tetracyclines on the course of psoriasis. , 1988, Journal of the American Academy of Dermatology.

[53]  N. Tsankov,et al.  ONSET OF PSORIASIS COINCIDENT WITH TETRACYCLINE THERAPY , 1988, The Australasian journal of dermatology.

[54]  C. Grattan Evidence of an association between bullous pemphigoid and psoriasis , 1985, The British journal of dermatology.

[55]  M. David,et al.  Coexistence of psoriasis vulgaris and bullous diseases. , 1985, Journal of the American Academy of Dermatology.

[56]  M. Lebwohl,et al.  Biologics and Psoriasis: The Beat Goes On. , 2019, Dermatologic clinics.

[57]  J. Wardle,et al.  Sleep and nighttime energy consumption in early childhood: a population‐based cohort study , 2015, Pediatric obesity.

[58]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[59]  Robert C. Wolpert,et al.  A Review of the , 1985 .